Published in J Immunol on June 01, 1975
A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax (1981) 1.90
Calcium-sensitive modulation of Ig capping: evidence supporting a cytoplasmic control of ligand-receptor complexes. J Exp Med (1976) 1.75
A pH-stabilizing role of voltage-gated proton channels in IgE-mediated activation of human basophils. Proc Natl Acad Sci U S A (2008) 1.30
Effects of modulators of arachidonic acid metabolism on the synthesis and release of slow-reacting substance of anaphylaxis. Br J Pharmacol (1979) 1.21
Living histamine-containing cells from the bronchial lumens of humans. Description and comparison of histamine content with cells of rhesus monkeys. J Clin Invest (1977) 1.20
Factor-dependent in vitro growth of human normal bone marrow-derived basophil-like cells. J Exp Med (1983) 1.04
Histaminase release from human granulocytes. J Exp Med (1976) 1.00
Anaphylactic relase of a basophil kallikrein-like activity. II. A mediator of immediate hypersensitivity reactions. J Clin Invest (1979) 0.96
Defective histamine release in chronic urticaria. J Clin Invest (1976) 0.93
Characterization of the histamine receptors in the guinea-pig lung: evidence for relaxant histamine H3 receptors in the trachea. Br J Pharmacol (1994) 0.89
Activation of human basophils by staphylococcal protein A. I. The role of cyclic AMP, arachidonic acid metabolites, microtubules and microfilaments. Clin Exp Immunol (1982) 0.88
In vitro histamine and serotonin release by radiographic contrast media (RCM). Complement-dependent and -independent release reaction and changes in ultrastructure of human blood cells. Clin Exp Immunol (1978) 0.88
Gene expression and production of tumour necrosis factor by a rat basophilic leukaemia cell line (RBL-2H3) with IgE receptor triggering. Immunology (1990) 0.86
Effects of silybin on histamine release from human basophil leucocytes. Br J Clin Pharmacol (1987) 0.80
IgE receptor-mediated mast-cell renin release. Am J Pathol (2013) 0.79
Increased in vitro histamine release by radiographic contrast media in patients with history of incompatibility. Clin Exp Immunol (1978) 0.77
Pharmacological control of human basophil histamine release stimulated by eosinophil granule major basic protein. Immunology (1989) 0.76
Histamine H₂ receptor signaling × environment interactions determine susceptibility to experimental allergic encephalomyelitis. FASEB J (2013) 0.76
Calcium ionophore A23187 as a secretagogue for rat mast cells: does it bypass inhibition by calcium flux blockers? Agents Actions (1982) 0.75
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Anaphylaxis. N Engl J Med (1991) 2.53
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol (1976) 1.45
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45
Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol (1991) 1.45
Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol (1994) 1.44
Kinins are generated during experimental rhinovirus colds. J Infect Dis (1988) 1.44
Properties of a subpopulation of T cells bearing histamine receptors. J Clin Invest (1975) 1.43
Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis (1988) 1.43
Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med (1969) 1.42
Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. J Immunol (1966) 1.41
Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy (1993) 1.41
Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest (1983) 1.41
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40
Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med (1981) 1.40
Induction of histamine secretion by polycations. Biochim Biophys Acta (1980) 1.39
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis (1991) 1.38
Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med (1984) 1.38
Heterogeneity of human mast cells. J Immunol (1983) 1.37
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37
Insect allergy: the state of the art. J Allergy Clin Immunol (1979) 1.35
Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol (1995) 1.33
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33
Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32
Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol (1987) 1.32
Recombinant IL-3 induces histamine release from human basophils. J Immunol (1989) 1.31
Studies on the mechanism of lymphocyte-mediated cytolysis. 3. The role of microfilaments and microtubules. J Immunol (1973) 1.31
Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. J Allergy Clin Immunol (1974) 1.30
A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol (1968) 1.28
Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol (1986) 1.28
Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.27
A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med (1971) 1.27
Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol (1999) 1.26
Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med (1996) 1.25
In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release. Immunology (1970) 1.24
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J Clin Invest (1989) 1.23
IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. J Immunol (1994) 1.23
Eosinophil chemotactic factor (ECF). II. Release from human polymorphonuclear leukocytes during phagocytosis. J Immunol (1976) 1.22
Release of eosinophil chemotactic factor from human polymorphonuclear neutrophils by calcium ionophore A23187 and phagocytosis. Nature (1975) 1.21
Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis (1988) 1.21
Hyperosmolar triggering of histamine release from human basophils. J Clin Invest (1981) 1.21
Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol (1981) 1.21
Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest (1979) 1.20
Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization. J Clin Invest (1979) 1.20
Diagnostic tests in ragweed hay fever. A comparison of direct skin tests, IgE antibody measurements, and basophil histamine release. J Allergy Clin Immunol (1973) 1.20
Human basophils: mediator release and cytokine production. Adv Immunol (2001) 1.20
The purification of human basophils. J Immunol (1980) 1.20
The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol (1980) 1.19
Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. J Immunol (1989) 1.17
IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest (1976) 1.17
Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. J Immunol (1979) 1.17
Basophil and mast cell degranulation: ultrastructural analysis of mechanisms of mediator release. Fed Proc (1983) 1.15